Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
Evid Based Complement Alternat Med. 2012;2012:794970. doi: 10.1155/2012/794970. Epub 2012 Dec 26.
Background. A Kampo medicine, Shahakusan (SHS), has been prescribed in late phase of infection that causes inflammations in the lung. But effect of SHS on viral infection in respiratory tract has never been reported. Objectives. To evaluate anti-influenza virus activity of SHS and its mode of actions through immune systems. Methods. SHS (0.3 g/kg/day) was orally administered to BALB/c miceforupper (URI) or lower respiratory tract infection (LRI) of influenza virus A/PR/8/34. The virus titer of nasal lavage fluid (NLF) at 5 or 2 day postinfection (p.i.) and cytokine mRNA expressions in mandibular lymph node or lung at 5 or 4 day p.i. were evaluated for URI or LRI, respectively. The histopathological examinations of lung tissue and NK cell activity in the splenocytes were also evaluated at 4 day p.i. on LRI. Results. When SHS was administered from 7 days before to 4 days p.i. for URI, the virus titer was significantly decreased in comparison with water-treated control, and IL-4, IL-1β, and IL-10 mRNA expression was decreased, but IL-12A mRNA expression was increased. Administration of SHS from one day before to one day p.i. for LRI significantly decreased the virus titer. SHS also decreased infiltration of inflammatory cells in the bronchoalveolar spaces and damage of desquamated mucosal epithelia of bronchiole, decreased IP-10 mRNA expression, and increased NK cell activity. Conclusion. SHS has no direct effect on influenza virus infection but exerts antiviral effect in mice by its immunomodulating activity through action of NK cells and anti-inflammatory activity in the lung.
一种汉方药,柴胡加龙骨牡蛎汤(SHS),已被用于治疗肺部炎症的感染后期。但 SHS 对呼吸道病毒感染的作用尚未见报道。目的:通过免疫系统评估 SHS 抗流感病毒的活性及其作用机制。方法:BALB/c 小鼠经口给予 SHS(0.3 g/kg/天),用于上呼吸道(URI)或下呼吸道(LRI)流感病毒 A/PR/8/34 的感染。在感染后第 5 天或第 2 天,通过鼻洗液(NLF)中的病毒滴度评估 URI,或在感染后第 5 天或第 4 天,通过下颌淋巴结或肺中的细胞因子 mRNA 表达评估 LRI。在感染后第 4 天,还评估了肺组织的组织病理学检查和脾细胞中的 NK 细胞活性。结果:当 SHS 用于 URI 时,从感染前 7 天开始至感染后 4 天给药,与水治疗对照组相比,病毒滴度显著降低,IL-4、IL-1β 和 IL-10 mRNA 表达降低,但 IL-12A mRNA 表达增加。当 SHS 用于 LRI 时,从感染前 1 天至感染后 1 天给药,病毒滴度显著降低。SHS 还减少了支气管肺泡空间中炎症细胞的浸润和支气管粘膜上皮的脱落损伤,降低了 IP-10 mRNA 表达,增加了 NK 细胞活性。结论:SHS 对流感病毒感染没有直接作用,但通过 NK 细胞的免疫调节活性和肺部的抗炎活性,在小鼠中发挥抗病毒作用。